GlassScriptPhysician profile
Walter D Brown
NPI 1053305482
$11,666.99
in general payments reported to CMS, 2019-2025
42 companies · $2,228 in 2025
The $2,228 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $953 · 2021: $1,800 · 2022: $1,393 · 2023: $1,756 · 2024: $1,867 · 2025: $2,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,791 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,791.11 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,259.64 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,202.28 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $974.36 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $868.78 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $819.94 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $429.11 | 2019-2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $426.55 | 2019-2025 | Uptravi, Opsumit |
| Insmed, INC. | $417.54 | 2020-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $394.87 | 2021-2025 | Acthar |
| Grifols USA, LLC | $355.96 | 2020-2025 | Prolastin-C Liquid |
| Amgen INC. | $285.44 | 2022-2025 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $223.29 | 2021-2022 | |
| Genentech USA, INC. | $208.80 | 2019-2023 | Xolair |
| Novartis Pharmaceuticals Corporation | $178.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $164.67 | 2023-2025 | Winrevair |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $158.60 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $150.56 | 2019-2022 | |
| Gilead Sciences, INC. | $135.67 | 2019-2022 | |
| United Therapeutics Corporation | $134.21 | 2019-2022 | |
| Intuitive Surgical, INC. | $123.76 | 2024 | |
| Viatris Specialty LLC | $109.32 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $88.16 | 2023-2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $56.40 | 2021 | |
| Paratek Pharmaceuticals, INC. | $51.11 | 2021 | |
| Pulmonx Corporation | $46.60 | 2021-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Allergan, INC. | $46.06 | 2019 | |
| Electromed, INC. | $40.40 | 2023-2024 | Smartvest |
| Philips North America LLC | $31.71 | 2023-2024 | (Ak6) Vest Therapy |
| Fisher & Paykel Healthcare INC | $30.45 | 2021 | |
| Getinge USA Sales, LLC | $27.34 | 2021 | |
| Pfizer INC. | $25.21 | 2022 | |
| Baxter Healthcare | $22.80 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Liquidia Technologies, INC. | $22.59 | 2025 | Yutrepia |
| Sanofi-Aventis U.S. LLC | $21.87 | 2020 | |
| Sunovion Pharmaceuticals INC. | $20.46 | 2019 | |
| Acacia Pharma INC | $20.29 | 2021 | |
| La Jolla Pharmaceutical Company | $19.77 | 2025 | Giapreza |
| Teva Pharmaceuticals USA, INC. | $17.37 | 2021 | |
| Circassia INC. | $15.68 | 2019 | |
| Livanova USA, INC. | $15.26 | 2020 | |
| Melinta Therapeutics, LLC | $14.23 | 2023 | Vabomere |
| Ekos Corporation | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.